Navigation Links
Eisai/Pfizer's Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimer's Disease
Date:2/4/2008

rovide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

For each disease examined, Decision Resources' Treatment Algorithms Insight Series provides the following:

-- Qualitative diagnosis and referral patterns for the United States

based on thought leader input and guideline recommendations.

-- Quantitative treatment algorithms based on patient-level claims data

Product share (class and specific compound level) within each line

of therapy (1st, 2nd, 3rd line).

-- Practicing physician opinion on why specific drugs are chosen for

certain patient populations.

-- Discussion of key drug combinations (including add versus switch

patterns) by lines of therapy.

-- Progression of therapy from key 1st line products (e.g., initial

treatment with Lipitor to 2nd line, 3rd line; initial treatment with

Zocor to 2nd line, 3rd line).

-- Pathway to key therapies from previous therapies (e.g., how much

Avandamet use is preceded by metformin, Avandia, or both as single

products?).

-- Qualitative analysis of 2-year forecast incorporating practicing

physician sentiment towards upcoming launches, changes in

reimbursement, etc.

About Decision Resources

Decision Resources, Inc., (http://www.DecisionResources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information,
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
2. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
5. Breakthrough Opportunity for Improving Patient Health
6. Cryolife Once Again Severely Maims an Innocent Knee Surgery Patient
7. Physicians Practice, Loma Linda Partner to Improve Patient Care in Southern California
8. Difficult to Treat Erectile Dysfunction Patients
9. TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders
10. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
11. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... December 18, 2014 With only 2 ... special on Sartorius Biohit products . The product ... pipettes, Picus Electronic Pipette Trade-in Program, and free pipette ... Safety officers around the world. They are ideal for ... features include:, ,     Full volume range of ...
(Date:12/17/2014)... NY (PRWEB) December 16, 2014 The ... changes since 2013, which is why IBISWorld updated its ... industry continues to benefit from an intensified focus on ... proposal for new emission standards for power plants and ... operators. According to IBISWorld Industry Analyst Sarah Kahn, “a ...
(Date:12/17/2014)... 17, 2014 Once more, EMAAR ... larger packaged waste water treatment plant to phase one ... City (KAEC). Two years ago Bioshaft successfully supplied and ... serving two residential towers with an occupancy of 900 ... quarter million gallons per day and was signed on ...
(Date:12/17/2014)... 16, 2014  Vermillion, Inc. (NASDAQ: VRML ... today announced the next step in its expanded strategy ... provider with the naming of current Chief Operating Officer, ... Officer, while current Chairman of the Board and CEO ... Chairman. These changes are effective January 1, 2015. ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4
... Legislature are bogged down in a budget fight, just like ... is in Wisconsin. But there's an important distinction between the ... the few areas of agreement, not a source of perpetual ... and Governor Tim Pawlenty are behind schedule in most ways ...
... Congress as well as the Wisconsin Legislature, it is becoming ... research to persuade fellow lawmakers that such science is unethical. ... public opinion about its relative merits is beginning to carry ... of life and the promise of science, the House of ...
... could offer treatment for the underlying process not ... second Governor's Business Plan Contest on Tuesday, ... , ,Mithridion, a University of Wisconsin-Madison spinoff, emerged as ... for the judges. Even before that, co-founder Jeff Johnson, ...
Cached Biology Technology:Feuds between UW and the Legislature should end for good of the state 2Feuds between UW and the Legislature should end for good of the state 3With ethics guidelines, political consensus emerging on stem-cell research 2With ethics guidelines, political consensus emerging on stem-cell research 3Alzheimer's drug firm and more winners named in Wisconsin business-plan contest 2Alzheimer's drug firm and more winners named in Wisconsin business-plan contest 3Alzheimer's drug firm and more winners named in Wisconsin business-plan contest 4
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the ... the post-password and Internet of Things era, today announced ... The venture round was led by Metamorphic Ventures with ... Venture Partners, VegasTechFund, and others.  LaunchKey has raised $4 ... to expand its team and bring LaunchKey to market ...
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ... flexible and robust – with the clinical data to ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has ... in the APAC Region 2015-2019"  report to their ... in this market is advances in technology. With ... upgrade biometric solutions to the latest standard that ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... Humans are having an effect on Earth,s ecosystems but it,s ... the planet we are causing. Now you can add an ... The only question is how large of an impact will ... issue of Science (Dec. 16, 2011), Arizona State ...
... Ill. Clinical gene therapy may be one step closer, ... molecules. A group of University of Illinois researchers, led ... short spiral-shaped proteins can efficiently deliver DNA segments to cells. ... Chemie. "The main idea is these are new ...
... identified a gene mutation that researchers estimate dates back to ... yet discovered. , Researchers with the Ohio State University Comprehensive ... J. Solove Research Institute led the study and estimate that ... ago. Only a mutation seen in cystic fibrosis that arose ...
Cached Biology News:Researchers assess effects of a world awash in nitrogen 2Let's do the twist: Spiral proteins are efficient gene delivery agents 2Let's do the twist: Spiral proteins are efficient gene delivery agents 3Scientists discover second-oldest gene mutation 2
... The Vybrant Apoptosis Assay Kit #4 ... changes that occur in the permeability of ... of both YO-PRO-1 and propidium iodide nucleic ... the plasma membranes of apoptotic cells and ...
Request Info...
... Western Blot Analysis Kit is an ... developed by Biochain. It detects protein ... or yoctomole (10 -24 M) ... parts: Millennium Enhancer, protein interaction system ...
Request Info...
Biology Products: